Affiliation: University College London
- Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigineRaju Kapoor
National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N3BG, UK
J Neurol Sci 274:54-6. 2008..Clinical trials of neuroprotection using blockers of sodium channels are now under way. There is no agreement yet on several aspects of trial design, but the situation should become clearer once the results of these trials are reported...
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trialRaju Kapoor
Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery and the Institute of Neurology, Queen Square, London, UK
Lancet Neurol 9:681-8. 2010..In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis...
- Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disabilityDavid Paling
Department of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK
J Cereb Blood Flow Metab 34:34-42. 2014..Bolus arrival time was longer in patients with greater disability independent of atrophy and T2 lesion load, suggesting alterations in cerebral arterial hemodynamics may be a marker of clinically relevant pathology. ..
- Sodium accumulation is associated with disability and a progressive course in multiple sclerosisDavid Paling
NMR Research Unit, Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
Brain 136:2305-17. 2013..Increased total sodium concentration is likely to reflect neuroaxonal pathophysiology leading to clinical progression and increased disability...
- Axonal protection achieved in a model of multiple sclerosis using lamotrigineDavid A Bechtold
Department of Clinical Neuroscience, King s College London, Guy s Campus, National Hospital for Neurology and Neurosurgery, London, UK
J Neurol 253:1542-51. 2006..5 %+/-38.5; lamotrigine: 10.4 %+/-12.5, P<0.01). The findings suggest that lamotrigine may provide a novel avenue for axonal protection in MS...
- Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trialRhian Raftopoulos
National Hospital for Neurology and Neurosurgery, London, UK University College London Institute of Neurology, London, UK Queen Square Multiple Sclerosis Centre, London, UK
Lancet Neurol 15:259-69. 2016..Inhibition of voltage-gated sodium channels is neuroprotective in preclinical models. In this study we aimed to establish whether sodium-channel inhibition with phenytoin is neuroprotective in patient with acute optic neuritis...
- Energy failure in multiple sclerosis and its investigation using MR techniquesDavid Paling
NMR Research Unit, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
J Neurol 258:2113-27. 2011....
- Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial designRaju Kapoor
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
Curr Opin Neurol 19:255-9. 2006..This review considers the rationale for different therapeutic strategies for neuroprotection and discusses the controversies of trial design...